A Comprehensive Guide to Achieving New York State Clinical Laboratory Evaluation Program Approval for Next-Generation...

Area of Science:

• Molecular Diagnostics
• Genomic Profiling
• Hematopoietic Neoplasms

Background:

• US FDA regulation of laboratory-developed tests (LDTs) as in vitro diagnostics is evolving.
• The New York State Department of Health's Clinical Laboratory Evaluation Program (CLEP) offers a framework for LDT oversight, especially for next-generation sequencing (NGS) assays.
• Limited peer-reviewed literature details the studies required for CLEP approval of NGS assays.

Purpose of the Study:

• To present the analytical validation of the Rapid Pan-Heme (RPPH) assay for genomic profiling of hematopoietic neoplasms.
• To demonstrate compliance with Clinical Laboratory Evaluation Program (CLEP) standards for assay validation.
• To provide insights into regulatory compliance and assay validation for molecular diagnostics.

Main Methods:

• Validation of the Rapid Pan-Heme (RPPH) assay, a next-generation sequencing panel targeting >400 genes.
• Assessment of analytical validation including accuracy, precision, and reproducibility according to CLEP guidelines.
• Orthogonal validation of variants and implementation of quality control metrics.

Main Results:

• The RPPH assay demonstrated achievement of CLEP's stringent analytical sensitivity and reproducibility criteria.
• All variants were orthogonally validated, and appropriate controls were utilized.
• Clinical reports generated by the RPPH assay were shown to align with CLEP requirements.

Conclusions:

• The RPPH assay is established as a robust molecular diagnostic tool for classifying hematopoietic malignancies.
• The study provides actionable insights for researchers on navigating regulatory compliance and assay validation in clinical settings.
• This work supports the implementation of standardized validation for genomic profiling assays under regulatory frameworks like CLEP.